Healthcare Reform in China
Scripp Business Insights, October 2011, Pages: 112
This report gives an overview of China’s demographics, overall healthcare infrastructure, and the need for healthcare reforms. It provides detailed coverage of China’s healthcare reform plans from the viewpoint of pharmaceutical companies, payers, and healthcare providers. Reforms and implications for various stakeholders are assessed and comments from 23 managers at Chinese hospitals included.
Features and benefits:
- Learn how healthcare is being reformed in China and the effects on various industry stakeholders.
- Develop strategies for successful market penetration in China.
- Understand the regulatory structures which affect how drugs are approved and reimbursed in China.
- Gain insights about the effects of reform from a Scrip Business Insights survey of 23 managers at Chinese hospitals.
- Evaluate the importance of tier 2 and 3 cities in China's pharmaceutical market.
Highlights:
- Historically, China had a very high out-of-pocket expenditure on healthcare. However, the proportion of out-of-pocket expenditure on healthcare dropped from 60% in 2001 to 40% in 2008 due to the increasing coverage of social health insurance schemes.
- China’s population will increase by 85m people between 2010 and 2020. 85% of this will be accounted for by an increase in the population of over 60s, which will prompt growth in markets for cardiovascular diseases, dementia, and other age-linked conditions. A sharp rise in lifestyle diseases such as diabetes and obesity is also underway.
- Reforms are set to present opportunities for pharma companies, CROs, medical device manufacturers, and private health insurance providers. Healthcare IT is also set for a boost, as the government begins to invest in electronic health records.
Your key questions answered:
- How is healthcare provision in China changing, and how can pharma companies capitalize on this?
- How will healthcare reform in China affect CROs and clinical research?
- What are the opinions of Chinese hospital managers on the effects of reform?
- What are the advantages and disadvantages for a company to have a product listed on the national drug reimbursement lists?
- How will medical device manufacturers and private health insurance providers be affected by healthcare reforms?
EXECUTIVE SUMMARY
China’s changing population
China’s healthcare system and the need for reform
Healthcare reform in China
Implications of reforms for stakeholders
China’s changing population
Summary
Introduction
Increasing population
Aging population
Change in therapeutic focus
The rise of the middle class and increase in spending power
Urbanization
City expansion in China
Maximizing the opportunity of smaller city markets
China’s healthcare system and the need for reform
Summary
Overview
History of Chinese healthcare
Regulatory structure and government departments
The Ministry of Health
The State Food and Drug Administration
Ministry of Human Resources and Social Security
National Development and Reform Commission
Other healthcare related agencies
New drug regulation laws
New drug registration procedures
Drug recalls
Organization of healthcare and the hospital system
Urban healthcare
Rural healthcare
Differences in hospital healthcare
Urban healthcare and rural healthcare
Pricing and reimbursement in China
Approving drugs for reimbursement
Traditional Chinese Medicine
Healthcare reform in China
Summary
Universal medical insurance
Basic Medical Insurance
Urban Resident Basic Medical Insurance
New Rural Cooperative Medical Insurance
Private insurance
Assessment of health insurance programs
Drug pricing reform
Essential Drug List
The National Reimbursement Drug List
Hospital reform
Increasing the number of community health clinics
Reform of hospital finance
Implications of reforms for stakeholders
Summary
Introduction
Pharmaceutical companies
Hospitals
Selected responses to three qualitative survey questions
Private hospital opportunities
Contract research organizations
Medical device companies
Private health insurance companies
Healthcare IT companies
Assessment and conclusion
Appendix
Scope
Methodology
Glossary/Abbreviations
References
Company press releases
Informa products
Questionnaire responses
Research procedure
Detailed questionnaire responses
TABLES
Table: China’s population composition and projections by age group
Table: China’s urban and rural population (m), 2000–50
Table: Composition of the expenditure for public health in China, 2001–08
Table: Evolution of social medical insurance in China
Table: Overview of China’s healthcare related agencies
Table: Urban and rural levels of healthcare
Table: Statistics on New Rural Cooperative Medical System, 2004–09
Table: Financing Structure of NRCMS in Xiangtan City (RMB), 2005–09
Table: Overview of government subsidised medical insurance programs
Table: Comparison of the top 10 international additions/removals of key drugs, 2004–09
Table: Utilization rate for community health centres, 2002–09
Table: Number of privately owned medical institutions in China, 2008
Table: Six hospital categories covered for the questionnaire
FIGURES
Figure: China’s population growth rate, 1990–2010
Figure: China’s population, 1990–2030
Figure: Diabetes prevalence in China, India, US, UK, and Japan, 2010
Figure: Average wage of employed persons in urban units in China, 1995–2009
Figure: China’s middle class population increase, 2010–15
Figure: China’s urban and rural population (m), 2000–50
Figure: Comparison of healthcare expenditure in the US and China
Figure: Composition of the expenditure for Public Health in China (2001–08)
Figure: Lists A and B on the NRDL
Figure: Repositioning of medical institutions
Figure: Decision criteria for pharmaceutical companies to seek listing on NRDL
Figure: Application and approval procedure for clinical trials
Figure: Private health insurance market opportunity in China ($bn), 2008–20
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
